Watch Dr. Brandon J Blue, Dr. Surbhi Sidana, Dr. Kenneth H. Shain and Mary Derome answer questions about the future of treatment during the CURE Educated Patient Multiple Myeloma Summit.
AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator
Study to Examine Safety of SP-420 in MDS and MF
News provided by
Share this article
Share this article
BOSTON, Feb. 23, 2021 /PRNewswire/ AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO). The opening of this trial in MDS and MF marks another critical step forward on the development path for SP-420, said AbFero CEO Thomas X. Neenan. Following the recently awarded Parkinson s research grants from EUREKA Eurostars and Cure Parkinson s, this trial is an additional building block in our strategy of developing safe chelators for both hematological indications and diseases of aging where iron is implicated.